NewsRx

Search our medical news database

Antisense Technology

Suppression of SPARC Expression Decreases Melanoma Tumorigenicity

Published in Gene Therapy Weekly, March 17th, 1997

Suppression of SPARC expression using a SPARC antisense expression vector in human melanoma cells resulted in complete abrogation of tumorgenicity in vivo.

The glycoprotein SPARC (secreted protein, acidic, and rich in cysteine) is a widely distributed glycoprotein found in human and murine tissue undergoing developmental regulation. SPARC expression has been found to be associated with morphogenesis, migration, and proliferative processes, and cell-matrix interactions, as well as being found to interact with extracellular matrix components, growth factors, and cytokines, and regulation of matrix metalloproteinase expression.

By having such diverse...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook